Company intelligence / Profile preview

ONCORAD

Ann Arbor, Michigan, United States

Ownership: Private
Development stage: Other

Overview

OncoRad is a biotechnology company focused on developing innovative radiopharmaceutical treatments for aggressive cancers, particularly glioblastoma multiforme. The company's core technology involves a proprietary liquid brachytherapy system designed to deliver targeted radiation directly to the site of a resected tumor, minimizing damage to healthy surrounding tissue. By utilizing specific radionuclides in a localized delivery format, OncoRad aims to improve survival outcomes and quality of life for patients with high-grade gliomas. Their lead program is currently undergoing clinical evaluation to establish safety and efficacy in patients with recurrent brain tumors.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalDeviceBrachytherapy
Industry: Biotech

Beyond the preview

Go deeper on ONCORAD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONCORAD.

Explore the full profile